Title
Agents of Change: Improving the Collaboration Among CAR-T Center Experts and Community-Based Clinicians for DLBCL Patients 

Target Audience
Community and referring hematologist-oncologists and hematologist providers including advanced practice practitioners and pharmacists who care for DLBCL patients.

Commercial Supporter
Supported by an educational grant from Bristol Myers Squibb.

Learning Objectives
1.    Assess the latest efficacy and safety data of available CD19-directed CAR T-cell therapies for relapsed or refractory DLBCL.
2.    Examine patient eligibility and logistical considerations to optimize the timely referral and integration of CAR T-cell therapy for patients with DLBCL.
3.    Apply strategies for the multidisciplinary care team to appropriately monitor and manage adverse events in patients with DLBCL throughout the CAR-T journey.
4.    Integrate shared decision-making and patient-centered strategies for patients with DLBCL throughout their CAR T-cell therapy journey.

Accredited Provider and Accreditation Statements
Accredited by Haymarket Medical Education

Joint Accreditation

 
In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

DISCLOSURE OF FINANCIAL RELATIONSHIPS POLICY
Haymarket Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

DISCLOSURE OF UNLABELED USE 
This IPCE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this IPCE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Bristol Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the accreditation of this activity, please contact cme.questions@haymarketmedical.com.

FACULTY
 
PROGRAM CHAIR

Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Steven Greenberg Chair
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, NY

Dr. Salles has disclosed the following relevant financial relationships:
Advisor: AbbVie Inc., BeiGene USA, Inc., Bristol Myers Squibb, Genentech, Inc. (a member of the Roche Group), Genmab A/S, Incyte Corp., Ipsen Biopharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma (a Gilead Company), Loxo Oncology, Inc./Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corp., Nurix.

Consultant: AbbVie Inc., atbtherapeutics, BeiGene USA, Inc., Bristol Myers Squibb, Debiopharm, Genentech, Inc. (a member of the Roche Group), Genmab A/S, Incyte Corp., Innate Pharma S.A., Ipsen Biopharmaceuticals, Inc., Kite Pharma (a Gilead Company), ModeX Therapeutics Inc, Molecular Partners, Nordic Nanovector ASA, Oma Therapeutics, Treeline Biosciences.

Research Funding: AbbVie Inc., Genmab A/S, Ipsen Biopharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Nurix.

All of the relevant financial relationships listed for this individual have been mitigated.
 

ACCREDITED PROVIDER DISCLOSURE  
None of the planners, reviewers, and Haymarket Medical Education staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.

METHOD OF PARTICIPATION/INSTRUCTIONS
To obtain credit, a score of 65% or better, on the post-assessment is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.

Instructions when Pharmacy Credit is offered
Pharmacists claiming CE for Pharmacist credit will be asked to provide NABP number and month/day of birth (unless the learner has provided the information in a previous activity). HME will automatically report the credit to CPE Monitor on the learner’s behalf.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline Assessment - 0.25 credit
• Self Instruction Module 1 – 0.25 credit
• Self Instruction Module 2 – 0.25 credit
• Self Instruction Module 3 – 0.25 credit
• Self Instruction Module 4 - 0.25 credit
• Self Instruction Module 5 - 0.25 credit
• Self Instruction Module 6 - 0.25 credit
• Group Challenge – 0.50 credit
• Live Group Discussion 1 - 0.50 credit
• Live Group Discussion 2 – 0.50 credit
• Action Plan Development - 0.75 credit
• Final Assessment - 0.25 credit

PRIVACY POLICY 
Haymarket Medical Education does not share the names and contact information of learners with any ineligible companies.